nature's tirzepatide for diabetes: on track to SURPASS current therapy #ᴡᴇɪɢʜᴛʟᴏssᴊᴏᴜʀɴᴇʏ, Just received my @joinmaxlife

The discovery of glucagon-like peptide-1 receptor agonists (GLP-1RAs) grew out of National Institutes of Health and Veterans Administration research in the 1980s and 90s

In respiratory disease, cellular damage and injury is mediated by an increased oxidant burden and/or decreased antioxidant defenses

While it is legal to prescribe it for weight loss, we currently choose not to do so, due to the possible impact on diabetic patients who require this medication

According to a large study published in The BMJ , adults with type 2 diabetes who started GLP-1 receptor agonists were more likely to develop alopecia than those taking SGLT-2 inhibitors or DPP-4 inhibitors (1 Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation Go to source) Trusted Source Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation Go to source)